Winning Formulary Battles in Wound Care: Why Clinical Evidence Alone Is Not Enough
A wound care company recently completed a Phase IV study demonstrating that their advanced dressing reduced healing time by 28 percent compared to the formulary standard. The data was robust. The clinical significance was clear. The tissue viability community recognised the advance.
Three months later, they lost a formulary review at a major NHS trust. The procurement committee voted to retain the incumbent product. The reason given was "insufficient evidence of cost-effectiveness."
The clinical evidence existed. The health economic argument existed. But the rep presenting to the committee could not communicate either with the confidence and precision the moment required. Under questioning from a sceptical procurement lead, they retreated to clinical language that the committee's financial decision-makers did not connect with.
This is not an isolated failure. It is a pattern that repeats across the wound care industry.
The formulary is the revenue gate
In wound care, more than perhaps any other medical device category, the formulary decision determines commercial success. Unlike surgical devices where individual surgeon preference drives purchasing, wound care products are selected at an institutional level. If your product is not on the formulary, it does not get used regardless of individual clinician preference.
This makes the formulary review the single highest-stakes conversation in wound care commercial selling. Win the formulary listing and you gain access to thousands of patients across the trust. Lose it and you are locked out until the next review cycle, which may be two to five years away.
The concentration of commercial value in a single decision point creates enormous pressure on the reps who present to these committees. And it exposes a capability gap that clinical evidence alone cannot fill.
Why evidence alone does not win formulary reviews
Formulary committees are not scientific review boards. They are multi-stakeholder groups with diverse priorities, limited time, and institutional inertia that favours the status quo.
A typical committee includes tissue viability nurses who evaluate clinical merit, pharmacy leads who consider cost and supply, procurement representatives who focus on total spending, and occasionally a clinician sponsor who may or may not attend the meeting where the decision is actually made.
Each member evaluates the submission through a different lens.
The tissue viability nurse is your closest ally. They understand the clinical evidence and appreciate the outcomes. But they may not be the loudest voice in the room, and they often cannot translate clinical benefits into the financial language that persuades procurement.
The pharmacy lead considers drug and device budgets as a whole. They need to understand budget impact: not just unit cost, but total cost implications including nursing time, dressing change frequency, and complication rates. They need this presented in their language, not clinical language.
The procurement representative defaults to unit cost comparison. They see a current product at £X per unit and your product at £1.3X per unit. Without a compelling total-cost argument, the conversation ends at price premium. They are not being obstructive. They are doing their job, which is to control expenditure.
The institutional inertia works against you. Committees prefer stability. Changing a formulary product creates training requirements, supply chain adjustments, and risk. The burden of proof falls entirely on the new product. "Good enough" often beats "better" when the switching costs are considered.
For a rep to win in this environment, they need to do far more than present clinical data. They need to translate that data into the language of every stakeholder in the room, handle challenges from each perspective, and make the case for change compelling enough to overcome institutional inertia.
The skills that win formulary battles
Having observed dozens of formulary presentations across the wound care industry, the difference between those that win and those that lose is rarely the evidence. It is almost always the communication.
Successful presentations open with the committee's problem, not the product's features. They frame the discussion around trust objectives: reducing pressure ulcer rates, meeting CQC standards, controlling costs through better outcomes. The product is positioned as the solution to the committee's problem, not a new item requesting approval.
Successful presenters anticipate and welcome challenges. When procurement asks about cost, they do not become defensive. They reframe confidently: "The unit cost is higher. The cost per healed wound is lower. Let me show you how that works in your specific patient population." They have practised this response enough times that it flows naturally rather than sounding rehearsed.
Successful submissions include health economic modelling specific to the trust. Generic national data is less compelling than analysis using the trust's own wound prevalence data, nursing costs, and patient volumes. The rep who has done this work and can present it fluently demonstrates partnership, not just salesmanship.
Successful follow-up manages the committee's decision process. The initial presentation is rarely the end. Committee members have questions. Additional data is requested. Objections surface between meetings. The rep who manages this process actively, addressing concerns individually and building coalition support, wins more than the one who presents and waits.
Where practice changes outcomes
Each of these skills is conversational. They are demonstrated in live interactions with committee members, procurement leads, and clinical stakeholders. They require fluency under pressure: the ability to respond to unexpected questions, reframe hostile challenges, and adapt the presentation based on room dynamics.
These are exactly the skills that benefit most from deliberate practice. And they are exactly the skills that most wound care training programmes fail to develop adequately.
Traditional product training covers the clinical evidence thoroughly. Marketing provides the sales aid and the health economic model. But nobody gives the rep practice presenting the economic model to a hostile audience. Nobody simulates the procurement director who interrupts with "just tell me why I should pay 30 percent more." Nobody rehearses the moment when the committee asks a question the rep does not have the answer to and needs to handle gracefully.
AI conversation simulation addresses this gap directly. Reps can practise formulary presentations with AI committee personas who challenge from every angle. The tissue viability nurse AI asks about clinical endpoints. The procurement AI pushes on cost. The pharmacy AI asks about budget impact modelling. The committee chair AI manages time pressure and asks the rep to summarise their key point in 30 seconds.
This practice builds the specific conversational fluency that wins formulary battles. Not product knowledge, which is necessary but insufficient. Conversational confidence under multi-stakeholder pressure.
A rep who has practised 15 formulary presentations with AI personas behaves fundamentally differently in the real committee room compared to one who has presented once or twice before. They are calmer. Their responses are more fluid. They handle unexpected challenges without losing their thread. They read the room better because their cognitive resources are not consumed by basic recall of their own arguments.
The compound effect of formulary wins
For wound care companies, the commercial impact of improving formulary win rates is enormous due to the binary nature of the decision.
A single formulary win at a large NHS trust might generate hundreds of thousands in annual revenue over a multi-year contract period. The difference between winning and losing that formulary review is not marginal. It is the difference between revenue and no revenue from that institution.
Improving the formulary presentation capability of even a few key account managers has outsized commercial impact. If your team presents to 20 formulary committees per year and your win rate improves from 40 percent to 55 percent, that is three additional trust contracts. The revenue impact typically dwarfs the investment in capability development.
This is the argument that Commercial Directors in wound care should be making to their leadership: formulary battles are won or lost in conversations. Investing in the conversational capability that wins those battles has a direct and measurable revenue return.
Platforms like TrainBox give wound care commercial teams the ability to practise formulary presentations, procurement negotiations, and TVN engagement at scale. Every rep and key account manager can rehearse the highest-stakes conversations in their role until fluency replaces anxiety and evidence-based confidence replaces uncertain improvisation.
TrainBox helps medical device teams practise real conversations so they're ready when it matters.